Home › Companies › PTC THERAPEUTICS INC. › 2023-2024

PTC THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and PTC THERAPEUTICS INC.’s Form 8-K, filed 2024-06-20 (Item 5.07 on EDGAR). Page generated 02 October 2026.

7Reported items
210Asset managers
1,703Fund votes
2024-06-18Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore PTC THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by PTC THERAPEUTICS INC.

These tallies are PTC THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-20 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

PTC THERAPEUTICS INC. — official shareholder meeting results, meeting held 2024-06-18
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Emma Reeve	63,383,975	--	--	2,829,938	4,104,129	Majority: yes
Elect Director: Michael Schmertzler	64,029,610	--	--	2,184,303	4,104,129	Majority: yes
Elect Director: Mary Smith	64,717,219	--	--	1,496,694	4,104,129	Majority: yes
Elect Director: Glenn D. Steele, Jr., M.D., Ph.D.	64,598,479	--	--	1,615,434	4,104,129	Majority: yes

Source: PTC THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-06-20 — read the filing on EDGAR.

How asset managers voted at the PTC THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 210 asset managers that disclosed a PTC THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of PTC THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the proxy statement.

SECTION 14A SAY-ON-PAY VOTES

Combines 10 wordings of this item as funds reported it.

99% fund support · no official result

FOR 99%

The 206 asset managers below cast 99% of the shares they voted on this item FOR (75,099,551 for, 793,532 against).

FOR: 75,099,551 (98.8%)AGAINST: 793,532 (1.0%)ABSTAIN: 127,056 (0.2%)NOT VOTED: 60 (0.0%)

Largest asset managers voting on “Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described ” at PTC THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	12,830,126	0	For
Wellington	8,252,924	0	For
RTW INVESTMENTS, LP	7,252,167	0	For
State Street	5,765,755	0	For
ARMISTICE CAPITAL, LLC	4,771,367	0	For
Fidelity	4,283,014	0	For
BlackRock	4,019,241	0	For
Camber Capital Management LP	4,000,000	0	For
Janus Henderson	2,974,624	0	For
Hartford	2,644,661	0	For
First Trust	1,502,307	0	For
FRANKLIN ADVISERS INC	1,396,000	0	For
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	1,313,500	0	For
JANUS INVESTMENT FUND	1,279,907	0	For
Charles Schwab	1,242,420	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,225,033	0	For
JACOBS LEVY EQUITY MANAGEMENT, INC	1,180,897	0	For
T. Rowe Price	1,080,772	0	For
DE Shaw	764,679	0	For
Northern Trust	645,495	49	For
FRANKLIN STRATEGIC SERIES	480,611	0	For
Nuveen	456,660	0	For
TIAA	453,589	0	For
ROCKEFELLER FINANCIAL LLC	438,419	0	For
PICTET ASSET MANAGEMENT SA	398,116	0	For

Showing the 25 largest of 206 asset managers. See all 206 in the interactive database.

2. RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.

AUDIT-RELATED

Combines 3 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 69 asset managers below cast 99.9% of the shares they voted on this item FOR (28,375,424 for, 359 against).

FOR: 28,375,424 (100.0%)AGAINST: 359 (0.0%)ABSTAIN: 13,290 (0.0%)

Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING” at PTC THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	12,562,259	0	0	For
Hartford	2,644,661	0	0	For
Fidelity	2,561,241	0	0	For
State Street	2,276,104	359	0	For
First Trust	1,493,029	0	0	For
JANUS INVESTMENT FUND	1,279,907	0	0	For
BlackRock	1,250,204	0	0	For
Charles Schwab	621,210	0	0	For
FRANKLIN STRATEGIC SERIES	480,611	0	0	For
T. Rowe Price	471,935	0	0	For
TIAA	453,589	0	0	For
Northwestern Mutual	346,916	0	0	For
Equitable	196,866	0	0	For
Direxion Shares ETF Trust	168,852	0	0	For
QUANTITATIVE MASTER SERIES LLC	134,307	0	0	For
New York Life	134,260	0	0	For
Russell Investments	115,013	0	0	For
JPMorgan	89,935	0	0	For
Lincoln Financial	79,319	0	0	For
Nationwide	77,570	0	0	For
Columbia Threadneedle	68,268	0	0	For
ProShares	61,937	0	0	For
John Hancock	60,064	0	0	For
Global X	58,426	0	0	For
Brighthouse	29,116	0	13,290	For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

3. Election of Four Class II Directors: Emma Reeve

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 63,383,975WITHHELD: 2,829,938

PTC THERAPEUTICS INC.’s own tally for this item (“Elect Director: Emma Reeve”): 63,383,975 for, 2,829,938 withheld, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,696,785 outstanding shares: 83% for, 4% withheld (86% of the company cast a for/withheld vote).

The 68 asset managers below cast 100% of the shares they voted on this item FOR (27,740,840 for, 0 against).

FOR 98%

FOR: 27,740,840 (97.8%)ABSTAIN: 636,267 (2.2%)

Largest asset managers voting on “Election of Four Class II Directors: Emma Reeve” at PTC THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	12,562,259	0	For
Hartford	2,644,661	0	For
Fidelity	2,561,241	0	For
State Street	2,276,216	247	For
First Trust	1,493,029	0	For
JANUS INVESTMENT FUND	1,279,907	0	For
BlackRock	1,250,204	0	For
Charles Schwab	621,210	0	For
FRANKLIN STRATEGIC SERIES	480,611	0	For
T. Rowe Price	0	471,935	Abstain
TIAA	453,589	0	For
Northwestern Mutual	346,916	0	For
Equitable	110,666	86,200	For
Direxion Shares ETF Trust	168,852	0	For
QUANTITATIVE MASTER SERIES LLC	134,307	0	For
New York Life	134,260	0	For
Russell Investments	115,013	0	For
JPMorgan	89,935	0	For
Lincoln Financial	79,319	0	For
Nationwide	77,570	0	For
Columbia Threadneedle	68,268	0	For
ProShares	61,937	0	For
John Hancock	60,064	0	For
Global X	58,426	0	For
Brighthouse	4,075	38,331	Abstain

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

4. Election of Four Class II Directors: Glenn D. Steele, Jr., M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 64,598,479WITHHELD: 1,615,434

PTC THERAPEUTICS INC.’s own tally for this item (“Elect Director: Glenn D. Steele, Jr., M.D., Ph.D.”): 64,598,479 for, 1,615,434 withheld, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,696,785 outstanding shares: 84% for, 2% withheld (86% of the company cast a for/withheld vote).

The 68 asset managers below cast 100% of the shares they voted on this item FOR (27,740,840 for, 0 against).

FOR 98%

FOR: 27,740,840 (97.8%)ABSTAIN: 636,267 (2.2%)

Largest asset managers voting on “Election of Four Class II Directors: Glenn D. Steele, Jr., M.D., Ph.D.” at PTC THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	12,562,259	0	For
Hartford	2,644,661	0	For
Fidelity	2,561,241	0	For
State Street	2,276,216	247	For
First Trust	1,493,029	0	For
JANUS INVESTMENT FUND	1,279,907	0	For
BlackRock	1,250,204	0	For
Charles Schwab	621,210	0	For
FRANKLIN STRATEGIC SERIES	480,611	0	For
T. Rowe Price	0	471,935	Abstain
TIAA	453,589	0	For
Northwestern Mutual	346,916	0	For
Equitable	110,666	86,200	For
Direxion Shares ETF Trust	168,852	0	For
QUANTITATIVE MASTER SERIES LLC	134,307	0	For
New York Life	134,260	0	For
Russell Investments	115,013	0	For
JPMorgan	89,935	0	For
Lincoln Financial	79,319	0	For
Nationwide	77,570	0	For
Columbia Threadneedle	68,268	0	For
ProShares	61,937	0	For
John Hancock	60,064	0	For
Global X	58,426	0	For
Brighthouse	4,075	38,331	Abstain

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

5. Election of Four Class II Directors: Mary Smith

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 64,717,219WITHHELD: 1,496,694

PTC THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mary Smith”): 64,717,219 for, 1,496,694 withheld, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,696,785 outstanding shares: 84% for, 2% withheld (86% of the company cast a for/withheld vote).

The 68 asset managers below cast 100% of the shares they voted on this item FOR (27,740,840 for, 0 against).

FOR 98%

FOR: 27,740,840 (97.8%)ABSTAIN: 636,267 (2.2%)

Largest asset managers voting on “Election of Four Class II Directors: Mary Smith” at PTC THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	12,562,259	0	For
Hartford	2,644,661	0	For
Fidelity	2,561,241	0	For
State Street	2,276,216	247	For
First Trust	1,493,029	0	For
JANUS INVESTMENT FUND	1,279,907	0	For
BlackRock	1,250,204	0	For
Charles Schwab	621,210	0	For
FRANKLIN STRATEGIC SERIES	480,611	0	For
T. Rowe Price	0	471,935	Abstain
TIAA	453,589	0	For
Northwestern Mutual	346,916	0	For
Equitable	110,666	86,200	For
Direxion Shares ETF Trust	168,852	0	For
QUANTITATIVE MASTER SERIES LLC	134,307	0	For
New York Life	134,260	0	For
Russell Investments	115,013	0	For
JPMorgan	89,935	0	For
Lincoln Financial	79,319	0	For
Nationwide	77,570	0	For
Columbia Threadneedle	68,268	0	For
ProShares	61,937	0	For
John Hancock	60,064	0	For
Global X	58,426	0	For
Brighthouse	4,075	38,331	Abstain

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

6. Election of Four Class II Directors: Michael Schmertzler

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 64,029,610WITHHELD: 2,184,303

PTC THERAPEUTICS INC.’s own tally for this item (“Elect Director: Michael Schmertzler”): 64,029,610 for, 2,184,303 withheld, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,696,785 outstanding shares: 83% for, 3% withheld (86% of the company cast a for/withheld vote).

The 68 asset managers below cast 100% of the shares they voted on this item FOR (27,720,683 for, 0 against).

FOR 98%

FOR: 27,720,683 (97.7%)ABSTAIN: 656,424 (2.3%)

Largest asset managers voting on “Election of Four Class II Directors: Michael Schmertzler” at PTC THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	12,562,259	0	For
Hartford	2,644,661	0	For
Fidelity	2,561,241	0	For
State Street	2,275,565	898	For
First Trust	1,493,029	0	For
JANUS INVESTMENT FUND	1,279,907	0	For
BlackRock	1,250,204	0	For
Charles Schwab	621,210	0	For
FRANKLIN STRATEGIC SERIES	480,611	0	For
T. Rowe Price	0	471,935	Abstain
TIAA	453,589	0	For
Northwestern Mutual	346,916	0	For
Equitable	110,666	86,200	For
Direxion Shares ETF Trust	168,852	0	For
QUANTITATIVE MASTER SERIES LLC	134,307	0	For
New York Life	134,260	0	For
Russell Investments	115,013	0	For
JPMorgan	89,935	0	For
Lincoln Financial	79,319	0	For
Nationwide	77,570	0	For
Columbia Threadneedle	68,268	0	For
ProShares	61,937	0	For
John Hancock	60,064	0	For
Global X	58,426	0	For
Brighthouse	4,075	38,331	Abstain

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

7. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

98% fund support · no official result

FOR 98%

The 3 asset managers below cast 98% of the shares they voted on this item FOR (1,707,634 for, 27,974 against).

FOR: 1,707,634 (98.4%)AGAINST: 27,974 (1.6%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at PTC THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
ADAGE CAPITAL PARTNERS GP, L.L.C.	1,170,000	0	For
JPMorgan	537,634	0	For
Desjardins Global Asset Management Inc.	0	27,974	Against

Largest PTC THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked by the number of PTC THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 76,696,785 shares outstanding at the time of that meeting.

Top PTC THERAPEUTICS INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	16.73%
2	Wellington	10.76%
3	RTW INVESTMENTS, LP	9.46%
4	State Street	7.52%
5	ARMISTICE CAPITAL, LLC	6.22%
6	Fidelity	5.58%
7	BlackRock	5.24%
8	Camber Capital Management LP	5.22%
9	Janus Henderson	3.88%
10	Hartford	3.45%

Reported PTC THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

PTC THERAPEUTICS INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Wellington Management	11.61%	13F
Vanguard Group	10.81%	13F
RTW Investments, LP	9.68%	DEF14A
BlackRock	9.30%	13F
Armistice Capital, LLC	8.95%	DEF14A
State Street	5.36%	13F
Camber Capital Management LP	5.22%	DEF14A
Michael Schmertzler	2.25%	DEF14A
Geode Capital	2.17%	13F
FMR (Fidelity)	2.10%	13F

Percentages above are of 76,696,785 shares outstanding, as reported by PTC THERAPEUTICS INC. on its Form 10-Q dated 2024-04-23 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PTC THERAPEUTICS INC.’s 10-Q dated 2024-04-23. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At PTC THERAPEUTICS INC.'s shareholder meeting held 2024-06-18, in the 2023-2024 proxy season, 210 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,703 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. PTC THERAPEUTICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — Approval on a non-binding, advisory basis, of the Company's named executive officer… — the reporting funds cast 99% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

PTC THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.